Hydroxychloroquine
- Generic Name
- Hydroxychloroquine
- Brand Names
- Plaquenil, Sovuna
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3O
- CAS Number
- 118-42-3
- Unique Ingredient Identifier
- 4QWG6N8QKH
- Background
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of quinacrine with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2.
The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.
Hydroxychloroquine was granted FDA approval on 18 April 1955.
A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.
- Indication
Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.
- Associated Conditions
- Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
- Associated Therapies
- -
Hydroxychloroquine and Cognitive Function After Surgery
- Conditions
- Interventions
- First Posted Date
- 2017-01-19
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Duke University
- Target Recruit Count
- 24
- Registration Number
- NCT03025087
- Locations
- 🇺🇸
Duke Health, Durham, North Carolina, United States
Biological Effects of Agent on PAR-4 Levels With Resected Solid Tumors
- First Posted Date
- 2017-01-10
- Last Posted Date
- 2022-01-25
- Lead Sponsor
- Peng Wang, MD PhD
- Target Recruit Count
- 38
- Registration Number
- NCT03015324
- Locations
- 🇺🇸
University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT02942381
- Locations
- 🇨🇳
Peking University First Hospital, BeiJing, Beijing, China
Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy
- Conditions
- Interventions
- First Posted Date
- 2016-10-12
- Last Posted Date
- 2021-07-27
- Target Recruit Count
- 136
- Registration Number
- NCT02930343
- Locations
- 🇮🇳
Department of Clinical Immunology , Jawaharlal Institute of Post graduate Medical Educationa and Research, Pondicherry, India
Hydroxychloroquine in Primary Progressive Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 35
- Registration Number
- NCT02913157
- Locations
- 🇨🇦
MS Clinic Foothills Medical Centre, Calgary, Alberta, Canada
The Influence of Plaquenil/Hydroxychloroquine (HCQ) on Insulin Secretion
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 40
- Registration Number
- NCT02910076
Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 98
- Registration Number
- NCT02765594
- Locations
- 🇨🇳
Peing Union Medical College Hospital, Beijing, China
Circulating MicroRNAs in Understanding Pathogenesis of Systemic Lupus Erythematosis
- Conditions
- Interventions
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2016-04-29
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 100
- Registration Number
- NCT02756546
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
- Conditions
- Interventions
- Other: No systemic corticosteroidOther: No antiviral agent for COVID-19Other: No immune modulation for COVID-19Drug: Standard course macrolideOther: No antiviral agent for influenzaDrug: Local standard venous thromboprophylaxisOther: No immunoglobulinOther: No simvastatinOther: No cysteamineOther: No Immune Modulator for InfluenzaOther: No vitamin COther: No antiplateletProcedure: Clinician-preferred mechanical ventilation strategyOther: No renin-angiotensin system inhibitorOther: No endothelial modulatorDrug: CeftriaxoneDrug: Moxifloxacin or LevofloxacinDrug: Extended course macrolideDrug: Fixed-duration HydrocortisoneDrug: Five-days oseltamivirDrug: Lopinavir / RitonavirBiological: Convalescent plasmaDrug: Angiotensin converting enzyme inhibitorDrug: Nirmatrelvir/ritonavirDrug: Therapeutic dose anticoagulationProcedure: Protocolised mechanical ventilation strategyDrug: Interferon beta-1aDrug: Vitamin CDrug: SimvastatinDrug: AspirinDrug: EritoranDrug: CysteamineDrug: ImatinibDrug: Shock-dependent hydrocortisoneDrug: Ten-days oseltamivirDrug: P2Y12 inhibitorDrug: Angiotensin Receptor BlockersDrug: Conventional low dose thromboprophylaxisBiological: Delayed administration of convalescent plasmaDrug: Piperacillin-tazobactamDrug: HydroxychloroquineDrug: AnakinraDrug: ApremilastDrug: BaricitinibDrug: RemdesivirDrug: Fixed-duration higher dose HydrocortisoneDrug: Hydroxychloroquine + lopinavir/ritonavirDrug: Intermediate dose thromboprophylaxisDrug: Nirmatrelvir/ritonavir + remdesivirDrug: ARB + DMX-200Drug: CeftarolineDrug: Baloxavir MarboxilDrug: TocilizumabDrug: Amoxicillin-clavulanateDrug: Fixed-duration dexamethasoneDrug: Five-days oseltamivir + baloxavir marboxilDrug: Continuation of therapeutic dose anticoagulationDrug: IvermectinDrug: SarilumabDrug: Ten-days oseltamivir + baloxavir marboxil
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 20000
- Registration Number
- NCT02735707
- Locations
- 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada
🇺🇸University of Illinois Health, Chicago, Illinois, United States
🇦🇺Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia
STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC)
- Conditions
- Interventions
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- University College, London
- Target Recruit Count
- 72
- Registration Number
- NCT02722369
- Locations
- 🇬🇧
UCLH, London, United Kingdom
🇬🇧The Christie, Manchester, United Kingdom
🇬🇧East and North Herts NHS Foundation Trust, Northwood, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.